menu
    • menu

    Company profile for BioLineRx

    NEW Drugs in Dev: 8
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    BioLineRx is a clinical-stage biopharmaceutical company focused on oncology. The Company in-licenses novel compounds, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization. BioLineRx’s leading therapeutic candidates are: BL-8040, a cancer therapy platform, which has successfully completed a Phase 2a study for relap...
    BioLineRx is a clinical-stage biopharmaceutical company focused on oncology. The Company in-licenses novel compounds, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization. BioLineRx’s leading therapeutic candidates are: BL-8040, a cancer therapy platform, which has successfully completed a Phase 2a study for relapsed/refractory AML, is in the midst of a Phase 2b study as an AML consolidation treatment and has initiated a Phase 3 study in stem cell mobilization for autologous transplantation.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    BioLineRxIsrael Flag
    Country
    Country
    Israel
    Address
    Address
    Modi’in Technology Park 2 HaMa’ayan Street Modi’in 7177871
    Telephone
    Telephone
    +972-8-642-9100
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.biolinerx.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/biolinerx
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/biolinerx_ltd?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    BioLineRx, Hemispherian Dose First Patient in GBM Study
    BioLineRx, Hemispherian Dose First Patient in GBM Study

    28 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biolinerx-and-hemispherian-announce-first-patient-dosed-in-phase-12a-study-of-glix1-for-the-treatment-of-glioblastoma-gbm-302755515.html

    PR NEWSWIRE
    28 Apr 2026
    Share Share
    BiolineRx Starts Phase 1/2A Trial Of GLIX1 For Glioblastoma (GBM)
    BiolineRx Starts Phase 1/2A Trial Of GLIX1 For Glioblastoma (GBM)

    26 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biolinerx-announces-initiation-of-phase-12a-study-of-glix1-for-the-treatment-of-glioblastoma-gbm-302725980.html

    PR NEWSWIRE
    26 Mar 2026
    Share Share
    BioLinerx Unveils 2025 Financials And Corporate Update
    BioLinerx Unveils 2025 Financials And Corporate Update

    23 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biolinerx-reports-2025-financial-results-and-provides-corporate-update-302721933.html

    PR NEWSWIRE
    23 Mar 2026
    Share Share
    BioLinerx To Report 2025 Annual Results On March 23, 2026
    BioLinerx To Report 2025 Annual Results On March 23, 2026

    16 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biolinerx-to-report-2025-annual-results-on-march-23-2026-302714539.html

    PR NEWSWIRE
    16 Mar 2026
    Share Share
    Biolinerx Unveils Q3 2025 Financials And Corporate Update
    Biolinerx Unveils Q3 2025 Financials And Corporate Update

    24 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biolinerx-reports-third-quarter-2025-financial-results-and-provides-corporate-update-302624413.html

    PR NEWSWIRE
    24 Nov 2025
    Share Share
    Hemispherian Secures GLIX1 Patent for Solid Tumors
    Hemispherian Secures GLIX1 Patent for Solid Tumors

    19 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251119133483/en/Hemispherian-Announces-USPTO-Notice-of-Allowance-for-Key-GLIX1-Patent-Covering-Majority-of-Solid-Tumors

    BUSINESSWIRE
    19 Nov 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search